SuperworthQuest Diagnostics DGX
- Market cap
- $26.7B
- PE
- 25.7×
- 10y median 19.3×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.3×
- EV/EBIT
- 19.5×
- Revenue, 12 months
- $11.8B
- +9% on a year ago
- Net margin
- 9.2%
- Free cash flow yield
- 5.1%
Quest Diagnostics trades at 25.7× trailing earnings, pricier than 99% of the last ten years. Revenue was $11.8B over the last twelve months, up 9% on a year earlier with a 9% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.3B−2% | $2.4B+2% | $2.4B+3% | $2.5B+8% | $2.6B+15% | $2.7B+12% | $2.8B+15% | $2.8B+13% | $2.8B+7% | $2.9B+9% | $3B+10% | $3.1B+10% | |
| Cost of revenue | $1.6B−2% | $1.6B+2% | $1.6B+3% | $1.7B+9% | $1.8B+14% | $1.8B+12% | $1.8B+14% | $1.9B+11% | $1.9B+8% | $2B+9% | $2B+11% | $2.1B+10% |
| Gross profit | $736M−3% | $771M+0% | $804M+2% | $811M+8% | $858M+17% | $863M+12% | $943M+17% | $949M+17% | $910M+6% | $942M+9% | $1B+9% | $1B+10% |
| SG&A | $407M−28% | $440M+0% | $416M+0% | $448M+18% | $466M+15% | $476M+8% | $486M+17% | $501M+12% | $504M+8% | $504M+6% | $529M+9% | $523M+4% |
| $267M+98% | $300M−2% | $355M+2% | $330M−4% | $361M+35% | $346M+15% | $438M+23% | $386M+17% | $386M+7% | $399M+15% | $459M+5% | $479M+24% | |
| Interest expense | $46M+28% | $43M+16% | $44M+13% | $49M+23% | $65M+41% | $67M+56% | $67M+52% | $66M+35% | $64M−2% | $63M−6% | $63M−6% | $61M−8% |
| Pre-tax income | $237M+117% | $266M−4% | $314M−1% | $296M−1% | $299M+26% | $276M+4% | $384M+22% | $328M+11% | $330M+10% | $334M+21% | $412M+7% | $416M+27% |
| $40M | $66M+2% | $74M−1% | $65M−4% | $68M+70% | $59M−11% | $97M+31% | $77M+19% | $81M+19% | $74M+25% | $88M−9% | $99M+29% | |
| Net income | $192M+90% | $194M−4% | $229M−3% | $226M+0% | $222M+16% | $220M+13% | $282M+23% | $245M+8% | $245M+10% | $252M+15% | $320M+14% | $312M+27% |
| $1.75+99% | $1.72−3% | $2.03−1% | $1.99+2% | $1.91+9% | $1.94+13% | $2.47+22% | $2.16+9% | $2.17+14% | $2.24+16% | $2.84+15% | $2.78+29% | |
| 110M−4% | 112M−1% | 112M−2% | 113M−1% | 116M+6% | 113M+1% | 113M+1% | 113M+0% | 113M−3% | 112M−1% | 112M−1% | 112M−1% |
Gross profit: 74 periods, Q2 FY08 to Q3 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: Q4 FY08: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'. 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $3B | $3B to $3.1B | $2.68 | $2.64 to $2.72 | 10 |
| Q1 FY27 | $3B | $3B to $3.1B | $2.71 | $2.63 to $2.86 | 8 |
| Q2 FY27 | $3.2B | $3.2B to $3.2B | $3.10 | $3.06 to $3.15 | 4 |
| Q3 FY27 | $3.2B | $3.2B to $3.3B | $3.12 | $3.09 to $3.17 | 3 |
| Q4 FY27 | $3.2B | $3.2B to $3.2B | $2.95 | $2.92 to $3.00 | 4 |
| Q1 FY28 | $3.2B | $3.1B to $3.2B | $3.11 | $3.08 to $3.17 | 4 |
| Q2 FY28 | $3.3B | $3.3B to $3.3B | $3.37 | $3.33 to $3.42 | 5 |
| Q3 FY28 | $3.3B | $3.3B to $3.4B | $3.33 | $3.29 to $3.39 | 4 |
Peers
Companies in Medical - Diagnostics & Research nearest Quest Diagnostics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| IDXXIDEXX Laboratories | $44.1B | 39.4× | 55.0× | 35.9× | 9.7× | +13% | 25.0% |
| WATWaters | $44.6B | 113× | 29.2× | 29.2× | 9.6× | +52% | 3.6% |
| IQVIQVIA | $46B | 34.7× | 34.9× | 20.5× | 2.7× | +8% | 8.1% |
| AAgilent Technologies | $48.8B | 34.0× | 33.1× | 26.4× | 6.6× | +9% | 19.5% |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | n/m | 3.8× | +1% | 8.6% |
| Peer median | $37.1B | 39.3× | 34.7× | 29.2× | 6.7× | +8% | 13.1% |
More on Quest Diagnostics
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 20Diagnostics and research stocks with the lowest PE ratio
- #3of 28Diagnostics and research stocks with the highest free cash flow yield
- #3of 25Diagnostics and research stocks with the lowest EV/EBIT
- #7of 17Diagnostics and research stocks with the fastest earnings growth
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .